Thalidomide: What You Need To Know About Risks And Uses
From tragedy to therapy: Thalidomide's dual legacy of birth defects and effective treatments for myeloma and leprosy.
Authoritative facts about thalidomide from high-credibility sources including Mayo Clinic, MedlinePlus, and peer-reviewed literature.
What is thalidomide?
Thalidomide is an immunomodulatory agent originally developed as a sedative and antiemetic in the 1950s. It gained notoriety for causing severe congenital malformations, particularly phocomelia (shortened or absent limbs), when taken by pregnant women in the late 1950s and early 1960s, affecting over 10,000 children worldwide. Despite this tragedy, its anti-inflammatory and anti-angiogenic properties led to its repurposing for treating erythema nodosum leprosum (ENL), a complication of leprosy, and later multiple myeloma (MM), a blood cancer. Thalidomide works by inhibiting tumor necrosis factor-alpha (TNF-α), suppressing angiogenesis, and modulating immune responses, making it effective in conditions involving inflammation and abnormal blood vessel growth.
Today, thalidomide is available only through restricted distribution programs like the Thalidomide REMS (Risk Evaluation and Mitigation Strategy) in the US or iPLEDGE-equivalent systems elsewhere, due to its potent teratogenicity—even a single dose during early pregnancy (particularly 20-36 days post-conception) can cause limb defects, ocular, cardiac, gastrointestinal, and neurological malformations. It is administered orally as capsules, typically once daily at bedtime to minimize sedation.
History
Thalidomide was synthesized in 1953 by Chemie Grünenthal in Germany as a non-barbiturate sedative claimed to be safer than existing options. Marketed from 1957 as Contergan, Distaval, and other brands in over 40 countries, it was promoted for morning sickness in pregnancy without adequate testing. By 1961, Australian gynecologist William McBride and German pediatrician Widukind Lenz independently linked it to a surge in phocomelia cases, leading to rapid withdrawals. This disaster prompted global regulatory reforms, including the 1962 Kefauver-Harris Amendments in the US requiring proof of efficacy and safety.
In the 1990s, renewed interest emerged after trials showed efficacy in ENL and HIV-related aphthous ulcers. FDA approval for ENL came in 1998, followed by MM in 2006, often in combination with dexamethasone or chemotherapy. The tragedy underscored the need for rigorous preclinical teratogenicity testing, saving countless lives through stricter drug approvals.
Who gets thalidomide?
- Primary indications: Newly diagnosed multiple myeloma (in combination regimens like thalidomide-dexamethasone), relapsed/refractory MM, and erythema nodosum leprosum (ENL) unresponsive to corticosteroids or for maintenance.
- Off-label uses: Behçet disease (oral/genital ulcers), graft-versus-host disease (GVHD), actinic prurigo, lupus erythematosus, Sjögren syndrome, and certain cancers like Kaposi sarcoma.
- Patient profile: Adults with MM (median age 65-70) or multibacillary leprosy complications. Contraindicated in pregnancy, women of childbearing potential without contraception, and those with severe neuropathy or bradycardia.
Clinical features and diagnosis
Thalidomide is prescribed based on confirmed diagnoses: MM via bone marrow biopsy showing plasma cell proliferation; ENL via clinical reactional leprosy with painful nodules. No specific diagnostic test exists for thalidomide eligibility beyond standard workup. Baseline assessments include pregnancy testing (serum/urine), complete blood count (CBC), liver/renal function, and neurological exam for neuropathy risk.
Teratogenicity / Embryopathy / Embryofetopathy
Thalidomide’s hallmark risk is thalidomide embryopathy, affecting 20-30% of exposed fetuses during days 20-36 post-conception (4-8 weeks gestation). Key malformations include:
- Limbs: Phocomelia (73%), hypoplasia of arms/hands/legs/feet, radial aplasia, triphalangeal thumb.
- Eyes: Microphthalmia, coloboma, anotia (absent ears).
- Internal: Cardiac septal defects, duodenal atresia, renal malformations.
- Neurological: Motor deficits, autonomic dysfunction; up to 50% mortality in infancy.
Even post-withdrawal, non-survivors face lifelong complications like scoliosis, pulmonary issues. Survivors now adults (age 60+) experience secondary issues: hypertension, diabetes, neuropathy. Risk persists with analogs like lenalidomide.
Mechanism of action
Thalidomide’s pleiotropic effects include:
- TNF-α inhibition via cereblon-mediated ubiquitination/degradation of transcription factors.
- Anti-angiogenic via VEGF suppression.
- Immunomodulation: enhances T-cell/NK-cell activity, inhibits neutrophils.
- Sedative effects via GABA modulation (though minor at therapeutic doses).
These properties explain efficacy in MM (induces apoptosis, inhibits adhesion) and ENL (reduces inflammation).
Indications
| Condition | Regimen | Evidence Level |
|---|---|---|
| Multiple myeloma (newly diagnosed) | 200 mg daily + dexamethasone | FDA-approved |
| ENL | 100-300 mg/day; taper for maintenance | FDA-approved |
| ENL maintenance | Lowest effective dose | FDA-approved |
Differential diagnosis
{In dermatology context:} Distinguish ENL from type 2 leprosy reactions, Sweet syndrome, or panniculitis. For MM-related skin findings, rule out amyloidosis or plasmacytoma.
Investigations
- Pregnancy testing (weekly/monthly).
- CBC (monitor neutropenia, thrombocytopenia).
- Neurological exam/EMG for neuropathy.
- ECG for bradycardia.
- LFTs, lipids, glucose.
Management
Administration
Take at bedtime with water; do not break/dissolve capsules. Avoid grapefruit (CYP inhibition). Dose: MM 200 mg/day; ENL 100-400 mg/day.
Safety program
Mandatory REMS: Dual contraception (2 forms + abstinence), monthly pregnancy tests, no blood donation for 1 month post-discontinuation. Men: Use contraception; semen may carry risk (controversial).
Monitoring
- Weekly CBC first month, then monthly.
- Monthly neuro exams.
- qPM pregnancy tests.
Adverse effects
Sedation: 25-50%; dose-limiting.
Peripheral neuropathy: 20-50%; sensory > motor; may be irreversible.
Thromboembolism: 3-20%; higher with MM/dex.
Hematologic: Neutropenia (30%), thrombocytopenia.
Skin: Rash (20%), SJS/TEN/DRESS (rare, fatal).
Other: Constipation, edema, hypothyroidism, orthostasis, tumor lysis.
| Common (>10%) | Serious |
|---|---|
| Sedation, constipation, edema, neuropathy, fatigue | Teratogenicity, VTE, SJS/TEN, neutropenia, seizures |
Drug interactions
- Strong CYP1A2 inhibitors (ciprofloxacin): ↑ levels.
- Anticoagulants: Monitor.
- Progestin-only OCP: Ineffective.
Complications
Chronic neuropathy, secondary malignancies (MM context), infertility (rare), cardiac events.
Prevention
Strict REMS compliance, patient education, baseline risk assessment.
Prognosis
Excellent for ENL control; improves MM response rates (PFS doubled in trials). Discontinue if neuropathy worsens.
Guidelines
- NCCN MM: Preferred for transplant-ineligible.
- WHO Leprosy: First-line for ENL.
- FDA REMS mandatory.
Emerging treatments
Pomalidomide/lenalidomide (analogs with better profiles); CAR-T, bispecifics supplanting in MM.
Frequently Asked Questions
What is the risk of birth defects with thalidomide?
Extremely high: >20% if exposed in therapeutic window; absolute ban in pregnancy.
Can men taking thalidomide father children?
Use contraception; semen risk theoretical but program requires it.
How common is permanent neuropathy?
Up to 20%; monitor closely, reversible in <50%.
Is thalidomide chemotherapy?
No, immunomodulatory; often combined with chemo.
What if I miss a dose?
Skip; do not double. Contact prescriber.
References
- Thalidomide (oral route) – Description & Warnings — Mayo Clinic. 2023-05-01. https://www.mayoclinic.org/drugs-supplements/thalidomide-oral-route/description/drg-20066301
- Thalidomide: MedlinePlus Drug Information — MedlinePlus (National Library of Medicine). 2024-02-15. https://medlineplus.gov/druginfo/meds/a699032.html
- Thalomid (thalidomide): Uses, Side Effects, Dosage — GoodRx Health (citing FDA labeling). 2024-10-10. https://www.goodrx.com/thalomid/what-is
- Thalidomide capsules — Cleveland Clinic. 2023-11-20. https://my.clevelandclinic.org/health/drugs/18951-thalidomide-capsules
- Thalidomide: the tragedy of birth defects and effective treatment — PubMed (Expert Rev Clin Pharmacol). 2011-04-01. https://pubmed.ncbi.nlm.nih.gov/21507989/
- Thalidomide in Pregnancy — Medicines in Pregnancy (UKTIS). 2024-01-01. https://www.medicinesinpregnancy.org/leaflets-a-z/thalidomide/
Similar Articles
Read full bio of Sneha Tete
